AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03825315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAXI 120 U
Description: DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) 120 U (High Dose Group)
Study NCT02266654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital Notification
Description: Prehospital providers will notify the receiving hospital over the radio or telephone that they are transporting a patient who meets Sepsis Criteria
Study NCT04267848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04267848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04267848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04267848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT01874964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Methadone Maintenance
Description: Individuals who are enrolled in methadone maintenance treatment at the time of incarceration are maintained on pre-incarceration dosage levels of methadone during short-term (6 months or less)incarceration. They will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
Study NCT01874964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linkage to methadone maintenance
Description: Individuals in the comparison arm will undergo methadone detoxification during short term incarceration, however, they will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
Study NCT02620449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will be fed a low-additive diet as the primary intervention
Study NCT04267848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT04267848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT04267848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04267848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04267848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Undergo observation
Study NCT04267848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT04267848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT04267848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04267848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT04267848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT04267848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04267848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02954406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine intravenous infusion
Study NCT01944761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3-4 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes (group sessions) or 30 minutes (home-based sessions). Group session activities will include i) warm-up (i.e. walk/jog, games) \[10 mins\], ii) aerobic training/fitness games \[30 mins\], iii) organized sports \[30 mins\], iv) cool down (i.e. stretching, low intensity games) \[10 mins\] and v) snack and reward (15 mins).~Participants in the Group setting had three 90-minute group sessions per week. Participants in the Combined setting had two 90-minute group sessions and two 30-minute individual home-based sessions per week.
Study NCT02954406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion
Study NCT02954406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine intravenous infusion
Study NCT02954406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsule
Study NCT02954406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsule
Study NCT00778258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baked Milk
Description: At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.
Study NCT00778258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-baked Milk
Description: Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.
Study NCT01905228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL0137
Description: All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.~Number of Cycles: 2 or until progression or unacceptable toxicity develops
Study NCT00362271 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
Description: Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
Study NCT04870307 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dissemination and Implementation Research
Description: Dissemination and Implementation research involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D\&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.
Study NCT04432506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Given SC
Study NCT03825315 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
Study NCT01842074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
Study NCT02050529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Description: Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.
Study NCT02050529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
Study NCT02292277 — intervention group
Intervention type: DRUG
Intervention: Ticagrelor
Description: Oral loading dose of 180 mg ticagrelor.
Study NCT04432506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Given IV
Study NCT00583778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipratropium
Description: 0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses
Study NCT00583778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipratropium
Description: 0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses
Study NCT02167893 — intervention group
Intervention type: DRUG
Intervention: Leuprorelin acetate
Description: Leuprorelin acetate SR 11.25 mg injection kit
Study NCT00573469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D9421-C, 9mg
Description: D9421-C 9 mg was given once daily for 8 weeks.
Study NCT00573469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D9421-C, 15mg
Description: D9421-C 15 mg was given once daily for 8 weeks.
Study NCT00573469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D9421-C matching placebo was given once daily for 8 weeks.
Study NCT03111901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab solution
Study NCT03111901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 solution
Study NCT04432506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04432506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03924895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Study NCT03924895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Description: Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
Study NCT03924895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Description: Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
Study NCT03924895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Enfortumab vedotin 1.25 mg/kg by intravenous (IV) infusion, given on Days 1 and 8 of each 21-day cycle.
Study NCT04227769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra Prefilled Syringe
Description: Subcutaneous injection of 100 mg/ 0.67 ml of Kineret or placebo
Study NCT00609869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
Study NCT01677598 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
Study NCT00609869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was administered at 375 mg/m\^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
Study NCT03926624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFP-10917
Description: DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride
Study NCT02314897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LV pacing
Description: Left ventricular pacing lead implanted via the coronary sinus.
Study NCT02314897 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RV pacing
Description: Conventional right ventricular pacing.
Study NCT01613404 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.
Study NCT04412720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and Breathing Exercises
Description: Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, Buteyko Breathing Technique also will be performed during 20 minutes each exercise, in the same treatment session. During the first two weeks, the patient will learn the technique supervised by a physical therapist. In addition, the patients will receive a breathing exercise booklet for in-home training. Before and after each session, patients will be evaluated in relation to blood pressure, heart rate, oxygen saturation and asthma symptoms.
Study NCT04412720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic and Stretching Exercises
Description: Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, stretching exercises will be performing for major muscle groups, during 30 seconds each one. The patients will receive a stretching exercise booklet for in-home training.
Study NCT02108353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 2mg
Description: once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
Study NCT02108353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
Study NCT01366521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Monoclonal antibody
Study NCT00543140 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: REALIZE™ Swedish Adjustable Gastric Band
Description: Laparoscopic placement of the Swedish Adjustable Gastric Band
Study NCT04432194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplementation and Pulmonary Rehabilitation
Description: Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation
Study NCT04432194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation and Pulmonary Rehabilitation
Description: Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation
Study NCT03125343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: Continuous follow-up. All patients with complete response will be followed for ten years. Details from the follow-up schedule will be registered in clinical record forms including information on the endoscopic findings, MRI findings and digital examination.~They will be followed ever third month for the first two years as follows:~* PET-CT is optional, but can be performed at inclusion~* Pelvic MRI including diffusion weighted imaging according to appendix C.~* Clinical examination~* Endoscopy (flexible sigmoidoskopy) with photodocumentation~* CEA~After two years the patients will be followed every six month with:~* Pelvic MRI including diffusion weighted imaging according to appendix as at baseline~* Clinical examination~* Endoscopy with photodocumentation~* CEA
Study NCT03926624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: cytosine arabinoside (ara-C)
Study NCT03926624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine
Study NCT03787173 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimized
Description: Inspiratory trigger and Expiratory trigger settings optimized by investigator
Study NCT03787173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated
Description: Inspiratory trigger and Expiratory trigger settings automatized
Study NCT01730326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg
Study NCT01730326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen
Description: 50 mg
Study NCT04332497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
Study NCT04332497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
Study NCT02327390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node
Description: Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory
Study NCT02327390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: X-ACT
Description: Administered as an IV infusion
Study NCT03020134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir
Description: Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
Study NCT03020134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
Study NCT03020134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
Study NCT03020134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01027234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8418
Description: Single oral dose
Study NCT01027234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose
Study NCT03265002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
Study NCT03265002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Ingestion of 500ml water with 50ml lemon juice and 20g inulin
Study NCT03265002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium
Description: Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
Study NCT03265002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin and psyllium
Description: Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
Study NCT02893865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure treatment during three months with adherence recording
Study NCT02893865 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-continuous positive airway pressure
Description: Sham-continuous positive airway pressure during three months with adherence recording
Study NCT05064020 — intervention group
Intervention type: DRUG
Intervention: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
Description: Administer BIC/FTC/TAF 50/200/25 mg tablet by mouth once a day from day 1 to168.
Study NCT02617394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragm scanning - traditional method first
Description: The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.